AUPH Aurinia Pharmaceuticals Inc

Price (delayed)

$5.01

Market cap

$724.53M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$773.27M

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The ...

Highlights
The revenue has increased by 31% YoY and by 10% from the previous quarter
Aurinia Pharmaceuticals's EPS has increased by 29% YoY
The quick ratio has declined by 45% year-on-year and by 4.7% since the previous quarter
AUPH's equity is down by 7% year-on-year and by 3.6% since the previous quarter

Key stats

What are the main financial stats of AUPH
Market
Shares outstanding
144.62M
Market cap
$724.53M
Enterprise value
$773.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.9
Price to sales (P/S)
4.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.41
Earnings
Revenue
$175.51M
EBIT
-$74.69M
EBITDA
-$63.05M
Free cash flow
-$34.18M
Per share
EPS
-$0.54
Free cash flow per share
-$0.24
Book value per share
$2.63
Revenue per share
$1.23
TBVPS
$3.79
Balance sheet
Total assets
$548.06M
Total liabilities
$170.11M
Debt
$97.61M
Equity
$377.95M
Working capital
$347.61M
Liquidity
Debt to equity
0.26
Current ratio
5.5
Quick ratio
4.85
Net debt/EBITDA
-0.77
Margins
EBITDA margin
-35.9%
Gross margin
91.9%
Net margin
-44.5%
Operating margin
-52.2%
Efficiency
Return on assets
-14.8%
Return on equity
-20.1%
Return on invested capital
-16.1%
Return on capital employed
-15.9%
Return on sales
-42.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AUPH stock price

How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
0.2%
1 week
0%
1 month
-14.21%
1 year
-54.41%
YTD
-44.27%
QTD
-44.27%

Financial performance

How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$175.51M
Gross profit
$161.37M
Operating income
-$91.69M
Net income
-$78.02M
Gross margin
91.9%
Net margin
-44.5%
Aurinia Pharmaceuticals's net margin has increased by 45% YoY and by 8% QoQ
The operating margin has increased by 37% YoY and by 8% from the previous quarter
The revenue has increased by 31% YoY and by 10% from the previous quarter
The net income has increased by 28% YoY

Growth

What is Aurinia Pharmaceuticals's growth rate over time

Valuation

What is Aurinia Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.9
P/S
4.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.41
Aurinia Pharmaceuticals's EPS has increased by 29% YoY
The price to book (P/B) is 59% lower than the 5-year quarterly average of 4.6 and 44% lower than the last 4 quarters average of 3.4
AUPH's equity is down by 7% year-on-year and by 3.6% since the previous quarter
The stock's P/S is 100% less than its 5-year quarterly average of 1826.8 and 51% less than its last 4 quarters average of 8.4
The revenue has increased by 31% YoY and by 10% from the previous quarter

Efficiency

How efficient is Aurinia Pharmaceuticals business performance
AUPH's ROIC is up by 50% year-on-year and by 10% since the previous quarter
Aurinia Pharmaceuticals's return on sales has increased by 46% YoY and by 10% QoQ
The company's return on assets rose by 33% YoY and by 2.6% QoQ
The ROE has increased by 21% YoY but it has decreased by 3.1% from the previous quarter

Dividends

What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUPH.

Financial health

How did Aurinia Pharmaceuticals financials performed over time
The total liabilities has soared by 160% YoY and by 4.3% from the previous quarter
The quick ratio has declined by 45% year-on-year and by 4.7% since the previous quarter
Aurinia Pharmaceuticals's debt is 74% lower than its equity
The company's debt to equity rose by 8% QoQ
AUPH's equity is down by 7% year-on-year and by 3.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.